Hypertension Is Still Being Missed on a Large Scale in England
In a large cross-sectional analysis drawn from Our Future Health, high blood pressure remained both common and poorly controlled across adults in England. Using World Health Organization criteria, investigators identified hypertension in 37% of participants — a burden that climbed steeply with age and was already present in a meaningful share of younger adults. The most troubling signal was not just prevalence, but invisibility: 59% of participants with hypertension had never been diagnosed and were not taking blood pressure-lowering medication.
This is the biology of cardiovascular injury operating quietly in the background. Elevated arterial pressure does not need symptoms to damage blood vessels, increase left ventricular workload, accelerate atherosclerosis, and raise the risk of stroke and myocardial infarction. By the time headaches, chest pain, or neurologic symptoms appear, end-organ damage may already be underway.
The cohort was large enough to make the pattern difficult to dismiss. Participants joined Our Future Health between 2022 and 2025, and clinic blood pressure measurements were used to estimate how many adults had hypertension, how many already knew it, how many were treated, and how many remained uncontrolled despite medication. A person was classified as hypertensive if systolic pressure was at least 140 mmHg, diastolic pressure was at least 90 mmHg, or if blood pressure-lowering therapy was already in use.
Age, Sex, and Treatment Gaps Marked the Gradient of Risk
The age gradient was stark. Hypertension affected 15% of adults aged 18 to 39 years, then rose to 71% among people aged 80 years or older. Men carried a heavier burden than women, with age-standardized rates of 42% and 29%, respectively. Those differences fit established vascular epidemiology: arterial stiffness, cumulative salt sensitivity, metabolic risk, and longer exposure to adverse hemodynamics all push prevalence upward over time.
A single line from the data captures the bedside problem with unusual clarity: treatment did not guarantee control.
Among participants already taking one or more antihypertensive medications, 50% still had readings of 140/90 mmHg or higher. In practical terms, half of treated patients in this cohort were still exposed to pressures high enough to sustain vascular injury. Poor control can reflect underdosing, therapeutic inertia, low adherence, white-coat effects, resistant hypertension, or the failure to intensify therapy quickly enough after repeated elevated readings.
The study’s broader message is that detection and control are both failing at scale. Even before the question of treatment efficacy arises, many adults never reach the point where hypertension is formally recognized. Once identified, too many remain above threshold despite being in care. Those two failures feed the same downstream consequences: more strokes, more coronary events, more heart failure, and more premature death.
Why Current Detection Pathways May Miss Too Many Patients
The investigators argue that current NICE guidance may be part of the problem. Under that approach, several blood pressure measurements are required to confirm a diagnosis, and in some cases lifestyle change is recommended before medication is started. In theory, that reduces overtreatment. In practice, it can allow elevated blood pressure to persist without action, especially in patients who do not return promptly for repeated checks or who sit in the gray zone where clinicians hesitate to prescribe.
Wenyu Liu, the study’s lead author at Oxford Population Health, described hypertension as a silent killer and argued that the current detection and treatment pathway is not fit for purpose. The data support that view. The problem was not confined to a narrow subgroup or an isolated age band. It was broad, persistent, and visible even among younger adults who are not yet eligible for an NHS Health Check. More than 15% of that younger group already had high blood pressure, meaning the current age-based screening model may be waiting too long to intervene.
The physiology makes the policy issue more urgent. Blood pressure exposure accumulates over decades, and a delay of several years in diagnosis can translate into a substantial increase in lifetime vascular burden. Earlier detection opens a path to risk reduction before plaque destabilization, arterial remodeling, and small-vessel damage become entrenched. In that sense, the diagnostic window is not administrative; it is biological.
A Broader Prevention Strategy Could Reach More Than High-Risk Adults
Iain Turnbull, Deputy Chief Medical Officer at Our Future Health and a GP, said the findings mirror what is seen in general practice and called for more proactive detection of high blood pressure. He also pointed to treatment decisions based on predicted cardiovascular risk, not blood pressure alone. That approach matters because the danger of hypertension is not evenly distributed: the same reading can carry very different implications depending on age, sex, smoking status, diabetes, kidney disease, lipid burden, and prior vascular disease.
Professor Bryan Williams of the British Heart Foundation framed the public health consequence in concrete terms. High blood pressure remains the leading modifiable risk factor for cardiovascular disease and is linked to around half of heart attacks and strokes in the UK. If 59% of adults with hypertension do not know they have it, and half of those treated are still uncontrolled, then a large reservoir of preventable vascular risk remains untouched by routine care.
The clinical implication is straightforward: blood pressure checks need to move earlier, and treatment pathways need to move faster. Opportunistic screening in primary care, community settings, and other points of contact could identify patients long before they enter the stroke or coronary disease pathway. Yet earlier identification alone will not solve the problem unless clinicians also close the control gap with timely medication intensification, adherence support, and closer follow-up.
The study leaves one practical question hanging over English hypertension care: how much preventable cardiovascular disease is being allowed to accumulate because diagnosis comes late and control comes even later? The answer will depend on whether screening expands beyond the current framework and whether treatment decisions become more aggressive for people whose risk is already rising, even when symptoms are absent.